|
|
|
Volumn 18, Issue 103, 2009, Pages 202-204
|
|
Ustekinumab - Suspicion of carcinogenicity: Too great a risk for psoriasis patients
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIBIOTIC AGENT;
CYCLOSPORIN;
ETANERCEPT;
INFLIXIMAB;
LIVE VACCINE;
METHOTREXATE;
PLACEBO;
STELARA;
UNCLASSIFIED DRUG;
USTEKINUMAB;
IMMUNOGLOBULIN G;
IMMUNOLOGIC FACTOR;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 12;
INTERLEUKIN 23;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR RECEPTOR;
BACKACHE;
CANCER RISK;
CARCINOGENICITY;
CLINICAL TRIAL;
DEPRESSION;
DIARRHEA;
DIZZINESS;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG METABOLISM;
DRUG TREATMENT FAILURE;
HEART INFARCTION;
HERPES ZOSTER;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INFECTION;
INJECTION SITE REACTION;
MENTAL DISEASE;
MYALGIA;
MYCOSIS;
NONHUMAN;
PREGNANCY;
PSORIASIS;
PSORIASIS VULGARIS;
PUVA;
RESPIRATORY TRACT INFECTION;
RHINOPHARYNGITIS;
SALMONELLOSIS;
SCORING SYSTEM;
SHORT SURVEY;
SORE THROAT;
STROKE;
TREATMENT CONTRAINDICATION;
TREATMENT RESPONSE;
TUBERCULOSIS;
ANIMAL;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
DOUBLE BLIND PROCEDURE;
DRUG ANTAGONISM;
EUROPE;
NEOPLASM;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ANIMALS;
ANTIBODIES, MONOCLONAL;
DOUBLE-BLIND METHOD;
EUROPE;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOLOGIC FACTORS;
IMMUNOSUPPRESSIVE AGENTS;
INJECTIONS, SUBCUTANEOUS;
INTERLEUKIN-12;
INTERLEUKIN-23;
NEOPLASMS;
PSORIASIS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECEPTORS, TUMOR NECROSIS FACTOR;
TREATMENT OUTCOME;
|
|
EID: 70350654512
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (9)
|
|
References (13)
|
